SG11202109152UA - Hyaluronan conjugates and uses thereof - Google Patents

Hyaluronan conjugates and uses thereof

Info

Publication number
SG11202109152UA
SG11202109152UA SG11202109152UA SG11202109152UA SG11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA
Authority
SG
Singapore
Prior art keywords
hyaluronan conjugates
hyaluronan
conjugates
Prior art date
Application number
SG11202109152UA
Inventor
Szu-Yuan Lee
Ping-Shan Lai
Chih-An Lin
Original Assignee
Aihol Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aihol Corp filed Critical Aihol Corp
Publication of SG11202109152UA publication Critical patent/SG11202109152UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG11202109152UA 2019-06-03 2020-06-02 Hyaluronan conjugates and uses thereof SG11202109152UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856714P 2019-06-03 2019-06-03
PCT/US2020/035780 WO2020247407A1 (en) 2019-06-03 2020-06-02 Hyaluronan conjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11202109152UA true SG11202109152UA (en) 2021-12-30

Family

ID=73550112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109152UA SG11202109152UA (en) 2019-06-03 2020-06-02 Hyaluronan conjugates and uses thereof

Country Status (15)

Country Link
US (2) US11524079B2 (en)
EP (2) EP3976019A4 (en)
JP (1) JP7275320B2 (en)
KR (1) KR20210151062A (en)
CN (1) CN113660933B (en)
AU (1) AU2020288834B2 (en)
BR (1) BR112021019113A2 (en)
CA (1) CA3133671C (en)
CO (1) CO2021012240A2 (en)
EA (1) EA202192225A1 (en)
IL (1) IL287917A (en)
MX (1) MX2021013140A (en)
SG (1) SG11202109152UA (en)
TW (2) TWI737330B (en)
WO (2) WO2020247407A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080183A1 (en) * 2022-10-14 2024-04-18 国立大学法人東海国立大学機構 Glycan complex, drug carrier, and drug delivery system
CN115970046B (en) * 2022-12-02 2024-04-26 南京工业大学 Application of multifunctional hydrogel in preparation of medicine for treating diabetes wound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087552A2 (en) * 2001-05-01 2002-11-07 Mcgill University Androgen-mediated neuroprotection and uses thereof
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
ES2447025T3 (en) * 2005-07-12 2014-03-11 Ampio Pharmaceuticals, Inc. Methods and products for the treatment of diseases
CN103784960A (en) * 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 Therapeutic protocols using hyaluronan
KR100806088B1 (en) 2007-08-09 2008-02-21 고려대학교 산학협력단 Compositions for delivering nucleic acids using cationic polymer conjugates consisting of hyaluronic acid and polyethylenimine
WO2011148116A2 (en) 2010-05-27 2011-12-01 Laboratoire Idenov Modified hyaluronic acid, method for manufacturing same and uses thereof
US8895069B2 (en) 2011-05-16 2014-11-25 Postech Academy-Industry Foundation Drug delivery system using hyaluronic acid-peptide conjugate micelle
US20130116411A1 (en) 2011-09-06 2013-05-09 Allergan, Inc. Methods of making hyaluronic acid/collagen compositions
JP6275044B2 (en) * 2012-09-05 2018-02-07 中外製薬株式会社 Hyaluronic acid derivatives with amino acid and steryl groups introduced
MX2015011847A (en) 2013-03-08 2016-01-08 Allergan Inc Antibiotic conjugates linked with steroid drugs.
US10000582B2 (en) * 2013-04-02 2018-06-19 The Regents Of The University Of California Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
US9572832B2 (en) 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
WO2016007856A1 (en) * 2014-07-10 2016-01-14 Academia Sinica Multi-drug delivery system and uses thereof
US20160279108A1 (en) * 2015-02-24 2016-09-29 University Of Kansas Targeted mtor inhibitors
KR101818705B1 (en) 2015-07-20 2018-01-16 포항공과대학교 산학협력단 Cross-linked hyaluronic acid hydrogel encapsulating therapeutic drugs and uses thereof
WO2017120193A1 (en) 2016-01-04 2017-07-13 University Of Kansas Drug delivery compositions and methods
CZ2016826A3 (en) 2016-12-22 2018-07-04 Contipro A.S. A medicinal agent with a carrier based on hyaluronan and/or its derivatives, a method of the manufacture and use
TWI626043B (en) * 2017-06-13 2018-06-11 心悅生醫股份有限公司 Use of Lithium Benzoate for Treating Central Nervous System Disorders
TW201912152A (en) * 2017-08-30 2019-04-01 保羅 L 曼弗雷蒂 Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof

Also Published As

Publication number Publication date
US20200376132A1 (en) 2020-12-03
CA3133671C (en) 2023-12-19
AU2020288834B2 (en) 2022-12-22
JP2022539652A (en) 2022-09-13
CA3133671A1 (en) 2020-12-10
MX2021013140A (en) 2021-12-10
TW202110456A (en) 2021-03-16
EP3976019A1 (en) 2022-04-06
EP3976019A4 (en) 2023-03-01
KR20210151062A (en) 2021-12-13
CO2021012240A2 (en) 2021-09-30
AU2020288834A1 (en) 2021-09-16
TWI817065B (en) 2023-10-01
CN113660933A (en) 2021-11-16
WO2020247407A1 (en) 2020-12-10
WO2021247076A1 (en) 2021-12-09
BR112021019113A2 (en) 2021-12-14
TW202146051A (en) 2021-12-16
JP7275320B2 (en) 2023-05-17
US11524079B2 (en) 2022-12-13
EA202192225A1 (en) 2022-03-15
EP4157256A1 (en) 2023-04-05
IL287917A (en) 2022-01-01
CN113660933B (en) 2023-12-01
TWI737330B (en) 2021-08-21
US20230080473A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
EP3732185A4 (en) Conjugates and preparation and use thereof
IL286291A (en) Compounds and conjugates thereof
LT3579883T (en) Pyrrolobenzodiazepine-antibody conjugates
HUE054689T2 (en) Pyrrolobenzodiazepine-antibody conjugates
IL287391A (en) Amatoxin antibody-drug conjugates and uses thereof
GB201702031D0 (en) Pyrrolobenzodiazepine-antibody conjugates
EP3645041A4 (en) Anti-mertk agonistic antibody-drug conjugates and uses thereof
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
AU2016349786B2 (en) Anti-CD3-folate conjugates and their uses
IL287917A (en) Hyaluronan conjugates and uses thereof
IL291312A (en) Anti-ptcra antibody-drug conjugates and uses thereof
GB201820626D0 (en) Conjugates
EP3700533A4 (en) Sstr-targeted conjugates and formulations thereof
GB201818562D0 (en) Pyrrolobenzodiazephones and conjugates thereof
GB201903535D0 (en) Compounds and conjugates
GB201903541D0 (en) Compounds and conjugates
IL288681A (en) Pyrrolobenzodiazepine-antibody conjugates
GB201906997D0 (en) Conjugates
GB201900735D0 (en) Conjugates
GB201712101D0 (en) nOMV-ANTIGEN CONJUGATES AND USE THEREOF
GB201811332D0 (en) Pyrroloobenzodiazepine-antibody conjugates
GB201811335D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201721290D0 (en) Conjugates
GB201719906D0 (en) Pyrrolobenzodiazepine-antibody conjugates